Search

Your search keyword '"Ghelli A."' showing total 480 results

Search Constraints

Start Over You searched for: Author "Ghelli A." Remove constraint Author: "Ghelli A." Database Unpaywall Remove constraint Database: Unpaywall
480 results on '"Ghelli A."'

Search Results

2. Assessing the inhaled dose of nanomaterials by Nanoparticle Tracking Analysis (NTA) of exhaled breath condensate (EBC) and its relationship with lung inflammatory biomarkers

4. New insights into idebenone therapy in relation to NQO1

5. Genetic variants affecting NQO1 protein levels impact the efficacy of idebenone treatment in Leber hereditary optic neuropathy

6. Air pollution and oxidative stress in adults suffering from airway diseases. Insights from the Gene Environment Interactions in Respiratory Diseases (GEIRD) multi-case control study

8. ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment

13. Systematic Violence Monitoring to Reduce Underreporting and to Better Inform Workplace Violence Prevention Among Health Care Workers: Before-and-After Prospective Study

16. Occupational exposure to nanomaterials and biomarkers in exhaled air and urine: Insights from the NanoExplore international cohort

17. Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients

19. List of Contributors

24. Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations

27. 142 Short-Term Exposure to Nanomaterials and Effect Biomarkers at Local and Systemic Levels: dose-Response Modelling Results from the Nanoexplore Project

31. Abstract 6163: Fusion landscape in acute leukemias: A submerged world of not routinely characterized transcripts

32. Supplementary Figures S1-S4 from The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias

33. Supplementary Figures S1-S4 from The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias

35. Supplementary Figure 5 from A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function

36. Data from A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function

37. Supplementary Figure 3 from A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function

38. Supplementary Figure 2 from A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function

39. Supplementary Figure 5 from A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function

40. Supplementary Figure 1 from A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function

41. Supplementary Figure 4 from A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function

42. Supplementary Figure 3 from A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function

43. Data from A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function

44. Supplementary Figure 2 from A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function

45. Supplementary Figure 1 from A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function

46. Supplementary Methods and Figure Legends from A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function

47. Supplementary Figure 4 from A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function

48. Systematic Violence Monitoring to Reduce Underreporting and to Better Inform Workplace Violence Prevention Among Health Care Workers: Before-and-After Prospective Study (Preprint)

49. Negation-Closure for JSON Schema

50. O-194 Prevalence of workplace violence amongst healthcare workers: estimates from a before-after study on incident reporting in Northern Italy

Catalog

Books, media, physical & digital resources